Company Ribomic Inc.

Equities

4591

JP3974850004

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
86 ^JPY	+3.61%		+4.88%	-20.37%

Mar. 07	Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI
Feb. 20	Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Number of employees: 25

JPY in Million	2022	Weight	2023	Weight	Delta
Drug Discovery 100.0 %	81	100.0 %	66	100.0 %	-18.47%

JPY in Million	2022	Weight	2023	Weight	Delta
Japan 100.0 %	81	100.0 %	66	100.0 %	-18.47%

Managers	Title	Age	Since
Satoshi Yonebayashi DFI	Director of Finance/CFO	-	-
Yoshikazu Nakamura PSD	President	76	03-07-31
Yoshihide Nakamura CTO	Chief Tech/Sci/R&D Officer	-	-
Hisato Oiwa ADM	Chief Administrative Officer	-	-
Emiko Nakamura BRD	Director/Board Member	45	03-07-31
Kazumasa Akita PRN	Corporate Officer/Principal	-	-
Yoshimi Nakajima LAW	General Counsel	-	-
Taro Nishikido AUD	Comptroller/Controller/Auditor	-	-
Satoshi Ishimaru PRN	Corporate Officer/Principal	-	-
Kazuaki Aoki PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Toshiaki Nishihata BRD	Director/Board Member	75	15-06-30
Yoshikazu Nakamura PSD	President	76	03-07-31
Emiko Nakamura BRD	Director/Board Member	45	03-07-31
Toshiyuki Mori BRD	Director/Board Member	56	19-05-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	36,511,440	33,739,938 ( 92.41 %)	19,002 ( 0.0520 %)	92.41 %

Name	Equities	%	Valuation
Zenyaku Kogyo Co., Ltd. 1.613 %	575,800	1.613 %	353 823 ¥
Yoshikazu Nakamura 1.591 %	568,000	1.591 %	349 030 ¥
Hide Imazu 1.383 %	493,700	1.383 %	303 374 ¥
Fujimoto Pharmaceutical Corp. 0.8405 %	300,000	0.8405 %	184 347 ¥
Emiko Nakamura 0.8265 %	295,000	0.8265 %	181 275 ¥
Senya Matsufuji 0.1121 %	40,000	0.1121 %	24 580 ¥
RIBOMIC INC. 0.0171 %	6,100	0.0171 %	3 748 ¥

Name	Equities	%	Valuation
RIBOMIC INC. 0.02%	6,100	0.02%	3,748 $

Ribomic, Inc.

Shirokanedai Usui Building, 6/F 3-16-13 Shirokanedai

108-0071, Tokyo

http://www.ribomic.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RIBOMIC INC.	-20.37%	20.25M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs